Janney Montgomery Scott Starts Medifast (MED) at Buy; Multiple Channels Driving 25% EBITDA Growth

Janney Montgomery Scott initiates coverage on Medifast (NYSE: MED) with a Buy. PT $39.

JMS analyst says, "WCCs provide weekly medical supervision and cater to intense weight loss needs. By selling the Medifast program (basic program is $315 for 4-weeks) through multiple channels, Medifast is well positioned for a diverse set of consumer approaches to the sensitive challenge of weight loss. Consumers who want independence get that in Medifast Direct channel. TSFL provides one-on-one Health Coach ("HC") support for both weight loss and MLM business-building objectives. Lastly, WCC's provide maximum medical support at MED's maximum price point via location-based selling."

For more ratings news on Medifast click here and for the rating history of Medifast click here.

Shares of Medifast closed at $25.02 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform
• BMO Capital Starts Energy Fuels (UUUU) at Outperform